Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL

Table 2 Multivariate analysis for PSA-PFS

	Univariate analysis			Multivariate analysis
	HR	95% CI	P-value	HR	95% CI	P-value
≥ 75 years old at diagnosis	1.09	0.55–2.16	0.79	1.17	0.59–2.35	0.65
CAB therapy with GnRH antagonist	0.40	0.16–0.87	0.02	0.41	0.16–0.90	0.03
Bone metastasis positive	4.12	1.93–9.79	< 0.01	3.60	1.66–8.74	< 0.01
Gleason score ≥ 8	3.38	1.21–14.07	0.02	1.94	0.66–8.34	0.25

CAB combined androgen blockade, CI confidential interval, HR hazard ratio, PFS progression-free survival, PSA prostate-specific antigen

ISSN: 1471-2407